SCOPUS 정보 검색 플랫폼

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 1, 2000, Pages 7-12

Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence?

(8) Williams, R L a Adams, W a Chen, M L a Hare, D a Hussain, A a Lesko, L a Patnaik, R a Shah, V a

a UNITED STATES PHARMACOPEIA (United States)

Author keywords

Bioavailability; Bioequivalence; BioInternational; Clinical pharmacology; Pharmaceutical equivalence

Indexed keywords

BIOEQUIVALENCE; CLINICAL PHARMACOLOGY; DOCUMENTATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG LEGISLATION; DRUG POTENCY; DRUG QUALITY; INTERNATIONAL COOPERATION; REVIEW; UNITED STATES;

EID: 0033810572 PISSN: 03787966 EISSN: None Source Type: Journal
DOI: 10.1007/BF03190049 Document Type: Review

Times cited : (11)

References (26)

1
- 0031003468
- Learning versus confirming in clinical drug development
- (1997) Clin. Pharmcol. Ther. , vol.61 , pp. 275-291
- Sheiner, L.B.¹

2
- 85037935231
- US Department of Health and Human Services, Food and Drug Administration. 21 CFR 320.1, Office of the Federal Register, National Archives and Records Administration
- (1999)

3
- 0007938862
- Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Media, PA: Williams and Wilkins
- (1995)
- Rowland, M.¹ Tozer, T.N.²

4
- 85037941666
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Draft Guidance for Industry: BA and BE studies for orally administered drug products - General considerations
- (1999)

5
- 85037932827
- International Conference on Harmonization (ICH). Q6A specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances

6
- 85037932655
- US Department of Health Human Services, Food and Drug Administration, Center for Drug Evaluation Research. Approved drug products with therapeutic equivalence evaluations (The Orange Book), 19th edn. Office of Information Technology, Division of Database Management and Services
- (1999)

7
- 0025918379
- C(max)/AUC is a clearer measure than C(max) for absorption rates in investigations of bioequivalence
- (1991) Int. J. Clin. Pharmacol. Ther. Toxicol. , vol.29 , pp. 394-399
- Endrenyi, L.¹ Fritsch, S.² Yan, W.³

8
- 0026488257
- An alternative approach for assessment of rate of absorption in bioequivalence studies
- (1992) Pharm. Res. , vol.9 , pp. 1380-1385
- Chen, M.L.¹

9
- 0028226203
- Bioequivalence: Performance of several measures of rate of absorption
- (1994) Pharm. Res. , vol.11 , pp. 966-974
- Bois, F.Y.¹ Tozer, T.N.² Hauck, W.W.³ Chen, M.L.⁴ Patnaik, R.⁵ Williams, R.⁶

10
- 0028285930
- Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies
- (1994) J. Pharm. Sci. , vol.83 , pp. 212-215
- Lacey, L.F.¹ Keene, O.N.² Duquesnoy, C.³ Bye, A.⁴

11
- 0027987256
- Sensitivity of indirect metrics for assessing 'rate' in bioequivalence studies - Moving the 'goalposts' or changing the 'game'
- (1994) J. Pharm. Sci. , vol.83 , pp. 1554-1557
- Rostami-Hodjegan, A.¹ Jackson, P.R.² Tucker, G.T.³

12
- 0028989927
- Without extrapolation, C(max)/AUC is an effective metric in investigations of bioequivalence
- (1995) Pharm. Res. , vol.12 , pp. 937-942
- Tothfalusi, L.¹ Endrenyi, L.²

13
- 0029940802
- Absorption rate vs. exposure: Which is more useful for bioequivalence testing?
- (1996) Pharm. Res. , vol.13 , pp. 453-456
- Tozer, T.N.¹ Bois, F.Y.² Hauck, W.W.³ Chen, M.L.⁴ Williams, R.L.⁵

14
- 0031944438
- The duration of measuring partial AUCs for the assessment of bioequivalence
- (1997) Pharm. Res. , vol.15 , pp. 399-404
- Endrenyi, L.¹ Csizmadia, F.² Tothfalusi, L.³ Balch, A.⁴ Chen, M.L.⁵

15
- 85037923725
- US Department of Health and Human Services, Food and Drug Administration: 21 CFR 320.24, the Office of the Federal Register, National Archives and Records Administration
- (1999)

16
- 0032698154
- Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling
- (1999) Clin. Pharmacol. Ther. , vol.66 , pp. 346-357
- Singh, G.J.P.¹ Adams, W.P.² Lesko, L.J.³

17
- 0004228312
- Draft Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on a biopharmaceutics classification system
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research
- (1999)

18
- 0004324584
- Guidance on statistical procedures for bioequivalence studies using s standard two-treatment crossover design
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation Research
- (1992)

19
- 0007935319
- Individual bioequivalence criterion: Regulatory considerations
- In press
- (1999) Stat. Med.
- Chen, M.L.¹ Patnaik, R.² Hauck, W.W.³ Schuirmann, D.J.⁴ Hyslop, T.⁵ Williams, R.L.⁶

20
- 85037934220
- European Court of Justice, Case C-368/96
- (1998)

21
- 85037947977
- Federal Register
- (1997) , vol.62 , pp. 14917-14918

22
- 85037945396
- US Department of Health and Human Services, Food and Drug Administration International Conference on Harmonization (ICH): E5 Ethnic factors In the acceptability of foreign clinical data
- (1998)

23
- 0025743320
- The intellectual health of clinical drug evaluation
- (1991) Clin. Pharmacol. Ther. , vol.50 , pp. 4-9
- Sheiner, L.B.¹

24
- 0025859676
- Lack of pharmacokinetic interaction as an equivalence problem
- (1991) Int. J. Clin. Pharmacol. Ther. , vol.29 , pp. 323-328
- Steinijans, V.W.¹ Hartmann, M.² Huber, R.³ Radtke, H.W.⁴

25
- 85037930233
- Early phase clinical studies: A regulatory perspective. Clinical Development of New Drugs and Therapeutic Agents: Art, Science, and New Frontiers, Center for Drug Development Science, Georgetown University, May 15, 1998
- (1998)
- Williams, R.L.¹

26
- 0007938864
- World Health Organization: Guidance on the selection of the comparator pharmaceutical product for equivalence assessment of interchangeable multi-source (generic) products. Geneva: WHO, In press
- (1999)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.